Calling All Laureates In Oncology Drug Manufacturing

By Rebecca Coutts, Ph.D., General Manager, PCI Pharma Services

The field of oncology has experienced rapid progression in recent years. Innovative discoveries in the understanding of the biology, immunology, and genetics of cancer are translating to medical treatments at an unprecedented pace. However, these treatments often entail highly potent or complex elements that require advanced consideration. CDMOs must be able to support these intricate manufacturing processes as well as the storage and distribution of time- and temperature-sensitive materials.

As CDMOs aim to keep pace with transformative oncology treatments, reducing development timelines while maintaining safety will be key to delivering critical oncology products to the patients who need them. Examine how leveraging tools and strategies such as predictive models, next generation and digital technologies, robotics and analytics, and artificial intelligence will enable manufacturing partners to meet the growing demand for safe and effective oncology treatments.